IOR study reveals how breast cancer therapy may be effective against COVID-19

The so-called “Selective Estrogen Receptor Modulators (SERMs)” treatments used in breast cancer therapy may be effective against COVID-19. A study conducted by the Institute of Oncology Research (IOR, affiliated to USI) based on data obtained from the Veneto Tumor Registry (Italy) has observed a lower risk of developing the coronavirus disease for women affected by hormonal-driven cancers subje...
More

Why Specific Genetic Alterations Matter in Prostate Cancer

A given substance may be fundamental for life or may serve as a poison. All depends on the specific dose. At first glance, this somewhat paradoxical principle in medicine was first coined by the Swiss physician Paracelsus more than half a millennium ago when he stated: “All things are poison, and nothing is without poison. Solely the dose determines that a thing is not a poison”. Centuries later, ...
More

Circulating plasma extracellular vesicles give new insights for monitoring and managing disease progression in prostate cancer patients

The Prostate Cancer Biology group, led by Dr. Giuseppina Carbone, of the Institute of Oncology Research has discovered in circulating plasma extracellular vesicles a novel biomarker that is associated with aggressive prostate cancer. The study by Albino et al. is published in Communications Biology and is available at https://doi.org/10.1038/s42003-020-01642-5. The work is a collaborative effort ...
More

Important steps forward in the anti-ageing therapy against metastases

Congratulations to Prof. Alimonti and his Molecular Oncology team at Institute of Oncology Research in Bellinzona, Switzerland, who discovered a genetic factor that determines whether ageing prostate cancer cells either die or become more aggressive. They have now found the genetic switch that determines the fate of senescent cells: the gene TIMP1. If this gene is inactive or absent in patients, f...
More

Congratulations to Prof. Alimonti and his Molecular Oncology team on receiving the Prostate Cancer Foundation Challenge Award

Prof. Alimonti from the Institute of Oncology Research (IOR) in Bellinzona, Switzerland and Prof. De Bono from the Institute of Cancer Research (ICR) in London, United Kingdom, just received this prestigious award for their work on targeting the host microbiota to reverse therapeutic resistance in lethal prostate cancers. Microbiota are microorganisms living in symbiosis with the host reported ...
More

New International PhD Program in Cancer Biology and Oncology 2020-2021

PhD at Institute of Oncology Research (IOR) means full immersion in a dynamic, challenging and intellectual community of students coming from different countries. The IOR provides high-level scientific education both for undergraduate students, experimental diploma thesis as well as graduate students. The PhD program, which includes seminars, lectures, classes and an annual retreat, is carried out...
More